$ALGS News

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus Infection

Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy Designation

Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos and Xiamen Amoytop sign deal for HBV therapy